Article ; Online: 2,5-Dimethyl-celecoxib induces early termination of inflammatory responses by transient macrophage accumulation and inhibits the progression of cardiac remodeling in a mouse model of cryoinjury-induced myocardial infarction.
Journal of pharmacological sciences
2024 Volume 154, Issue 2, Page(s) 97–107
Abstract: In our previous study, we reported that 2, 5-dimethyl-celecoxib (DM-C), a derivative of celecoxib, prevents cardiac remodeling in different mouse models of heart failure, including myocardial infarction (MI). The inflammatory response after MI affects ... ...
Abstract | In our previous study, we reported that 2, 5-dimethyl-celecoxib (DM-C), a derivative of celecoxib, prevents cardiac remodeling in different mouse models of heart failure, including myocardial infarction (MI). The inflammatory response after MI affects the progression of cardiac remodeling, wherein the immune cells, mainly macrophages, play crucial roles. Therefore, we evaluated the effect of DM-C on macrophages in a cryoinjury-induced myocardial infarction (CMI) mouse model. We observed that DM-C attenuated the deterioration of left ventricular ejection fraction and cardiac fibrosis 14 d after CMI. Gene expression of pro-inflammatory cytokines at the infarct site was reduced by DM-C treatment. Analysis of macrophage surface antigens revealed that DM-C induced transient accumulation of macrophages at the infarct site without affecting their polarization. In vitro experiments using peritoneal monocytes/macrophages revealed that DM-C did not directly increase the phagocytic ability of the macrophages but increased their number, thereby upregulating the clearance capacity. Moreover, DM-C rapidly excluded the cells expressing necrotic cell marker from the infarct site. These results suggested that DM-C enhanced the clearance capacity of macrophages by transiently increasing their number at the infarct site, and terminated the escape from the inflammatory phase earlier, thereby suppressing excessive cardiac remodeling and ameliorating cardiac dysfunction. |
---|---|
MeSH term(s) | Animals ; Mice ; Celecoxib/pharmacology ; Celecoxib/therapeutic use ; Stroke Volume ; Ventricular Remodeling ; Ventricular Function, Left ; Myocardial Infarction/drug therapy ; Macrophages ; Disease Models, Animal ; Pyrazoles ; Sulfonamides |
Chemical Substances | Celecoxib (JCX84Q7J1L) ; 2,5-dimethylcelecoxib ; Pyrazoles ; Sulfonamides |
Language | English |
Publishing date | 2024-01-03 |
Publishing country | Japan |
Document type | Journal Article |
ZDB-ID | 2104264-0 |
ISSN | 1347-8648 ; 1347-8613 |
ISSN (online) | 1347-8648 |
ISSN | 1347-8613 |
DOI | 10.1016/j.jphs.2024.01.001 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 237: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.